XTRA:BAYNPharmaceuticals
Assessing Bayer (XTRA:BAYN) Valuation After Asundexian’s Positive OCEANIC STROKE Phase III Results
Bayer (XTRA:BAYN) is back in focus after presenting Phase III OCEANIC-STROKE data, where its investigational Factor XIa inhibitor asundexian cut recurrent ischemic stroke without increasing major bleeding risk, bringing sharper attention to the pharma pipeline.
See our latest analysis for Bayer.
The OCEANIC-STROKE readout lands after a sharp shift in sentiment, with Bayer’s share price at €45.8 and a 90 day share price return of 75.78% contributing to a 1 year total shareholder return of...